cell and gene therapy

Will cell and gene therapies disrupt reimbursement?

https://deep-dive.pharmaphorum.com/magazine/disruptive-technologies/will-cell-and-gene-therapies-disrupt-drug-reimbursement/

Spectacular results for bluebird’s gene therapy in thalassemia

https://pharmaphorum.com/news/spectacular-results-for-bluebirds-gene-therapy-in-thalassemia/

Kite and Sangamo come together in $3bn cancer gene editing alliance

https://pharmaphorum.com/views-analysis-oncology/kite-sangamo-come-together-3bn-cancer-gene-editing-alliance/

Novartis snaps up ex-US partnership with Spark on gene therapy

https://pharmaphorum.com/news/novartis-snaps-ex-us-partnership-spark-gene-therapy/

Can Spark make a profit on its groundbreaking gene therapy?

https://pharmaphorum.com/news/can-spark-make-profit-groundbreaking-gene-therapy/

Sangamo edits living patient’s DNA for first time

https://pharmaphorum.com/news/us-doctors-gene-editing/

A gamechanger in haemophilia? SOBI unruffled by Roche’s impending therapy

https://pharmaphorum.com/news/gamechanger-haemophilia-sobi-unruffled-roches-impending-therapy/

uniQure presses ‘refresh’ on haemophilia gene therapy, gets FDA blessing

https://pharmaphorum.com/news/uniqure-plans-pivotal-haemophilia-gene-therapy-trial-next-year/

Gilead gains CAR-T approval, undercuts rival’s headline price

https://pharmaphorum.com/news/fda-approves-gilead-car-t-cancer-therapy/

1 2 3

Close in 10 seconds

Pharmaphorum.com

Search